OMass Therapeutics appoints Dr Nathalie Franchimont as Non-Executive Director
July 28, 2020

Oxford, 28 July 2020 – OMass Therapeutics (“OMass”), a biopharmaceutical company harnessing native mass spectrometry and other high definition biophysical technologies…

Read More
OMass Announces Publication in Nature Methods
May 15, 2020

Oxford, 15 May 2020 – OMass Therapeutics (“OMass”), a biotechnology company harnessing native mass spectrometry to drive drug discovery in high…

Read More
OMass Announces Acquisition of Pharmacology Capabilities from Excellerate Biosciences
February 25, 2020

– OMass acquires a pharmacology team led by industry expert, Professor Steven Charlton – Oxford, 25 February 2020 – OMass Therapeutics…

Read More
OMass Therapeutics Announces £27.5 Million Extended Series A Financing
February 17, 2020

– Developing a pipeline of small molecule therapeutics for patients with immunological and genetic disorders – Oxford, 17 February 2020 –…

Read More